BRIEF-Novo Nordisk Says Participants Treated With Zenagamtide Showed Body Weight Loss Up To 14.6% At Week 36 With Highest Dose Investigated, 40 Mg

June 5 (Reuters) - Novo Nordisk A/S NOVOb.CO:

  • NOVO NORDISK: ZENAGAMTIDE STUDY SHOWED BLOOD SUGAR REDUCTIONS IN ADULTS WITH TYPE 2 DIABETES VERSUS PLACEBO, UP TO 89.1% ACHIEVED A1C BELOW 7%

  • NOVO NORDISK: PARTICIPANTS TREATED WITH ZENAGAMTIDE SHOWED BODY WEIGHT LOSS UP TO 14.6% AT WEEK 36 WITH HIGHEST DOSE INVESTIGATED, 40 MG

  • NOVO NORDISK: ZENAGAMTIDE WILL ADVANCE INTO PHASE 3 CLINICAL TRIALS IN ADULTS WITH TYPE 2 DIABETES BASED ON RESULTS

  • NOVO NORDISK: NO APPARENT WEIGHT LOSS PLATEAU SEEN AT WEEK 36 WITH HIGHER DOSES OF ZENAGAMTIDE

Source text: ID:nPn3dqR6Wa

Further company coverage: [NOVOb.CO]


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.